Skip to content
Skip to navigation menu
26 February 2007
One of the UK's foremost scientists has joined Cardiff University to try to solve a rare genetic disease that affects babies and young children.
Dr Andy Tee has been awarded £750,000 to continue the progress he has already made in the study of tuberous sclerosis complex (TSC) a condition which affects one in 7,000 births and in which tumours, mostly benign, form in the brain, lungs, kidneys, heart and eyes.
Dr Tee will join an internationally-recognised team led by Professor Julian Samson in the School of Medicine’s Institute of Medical Genetics which is already undertaking pioneering drugs trails into the debilitating disease. The grant is the highest ever awarded by international cancer charity AICR (Association for International Cancer Research).
Dr Tee said: "Cardiff’s Institute of Medical Genetics is a world leader in the field of tumour development and I look forward to furthering my research here. This funding will provide resources for myself and a student researcher. There are many things being learned about this disease that are also relevant to many other cancers."
Tumours within the brain are the most detrimental and can cause seizures, learning difficulties and autism, and Dr Tee’s work has already helped piece together one of the missing parts of the puzzle - a novel method of identifying new components involved in cell growth.
Dr Mark Matfield, Association for International Cancer Research's scientific adviser said, "AICR is committed to supporting the brightest and best cancer researchers and it is particularly important to be able to help them at this crucial stage in their career.
"We believe that Dr Tee is an outstanding scientist and we are excited by his work and the prospect it holds for helping thousands of children who will suffer from this debilitating disease in the future."
Serious violence in England and Wales drops 12% in 2013
A holistic approach to targeting cancer
Developing new anti-cancer medicines
This is an externally hosted beta service offered by Google.